Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction
NCT07178145 on ClinicalTrials.gov · last registry update 2026-08-11
An unusually large phase 4: 192 participants, more than double the 75 typical for the stage. Due to report September 2029, alongside 12 other tracked readouts that quarter. Primary outcome, as filed: Epicardial adipose tissue (EAT) fatty acid composition (FAC). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for heart failure — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- University of Virginia
- Sponsor type
- Other
- Enrollment
- 192
- Started
- 2025-11-20
- Primary completion
- 2029-09 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Epicardial adipose tissue (EAT) fatty acid composition (FAC)
Conditions studied
Heart Failure Preserved Ejection Fraction · Epicardial Adipose Tissue
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.